Evidence map›Paper›PMID 37130532›Full record

ArticleLaryngo- rhino- otologie2023

Olfactory Function and Olfactory Disorders.

T Hummel, N Power Guerra, N Gunder, A Hähner, S Menzel

Open access · hybridAbstract read
In one paragraph

Article in Laryngo- rhino- otologie, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Olfactory Dysfunction in Allergic Rhinitis.Clinical reviews in allergy & immunology · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Editorial.Laryngo- rhino- otologie · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

T HummelInterdisziplinäres Zentrum Riechen und Schmecken, HNO Klinik, TU Dresden.
N Power GuerraRudolf-Zenker-Institut für Experimentelle Chirurgie, Medizinische Universität Rostock, Rostock.
N GunderUniversitäts-HNO Klinik Dresden, Dresden.
A HähnerInterdisziplinäres Zentrum Riechen und Schmecken, HNO Klinik, TU Dresden.
S MenzelInterdisziplinäres Zentrum Riechen und Schmecken, HNO Klinik, TU Dresden.
TU Dresden · DEUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sense of smell is important. This became especially clear to patients with infection-related olfactory loss during the SARS-CoV-2 pandemic. We react, for example, to the body odors of other humans. The sense of smell warns us of danger, and it allows us to perceive flavors when eating and drinking. In essence, this means quality of life. Therefore, anosmia must be taken seriously. Although olfactory receptor neurons are characterized by regenerative capacity, anosmia is relatively common with about 5 % of anosmic people in the general population. Olfactory disorders are classified according to their causes (e. g., infections of the upper respiratory tract, traumatic brain injury, chronic rhinosinusitis, age) with the resulting different therapeutic options and prognoses. Thorough history taking is therefore important. A wide variety of tools are available for diagnosis, ranging from short screening tests and detailed multidimensional test procedures to electrophysiological and imaging methods. Thus, quantitative olfactory disorders are easily assessable and traceable. For qualitative olfactory disorders such as parosmia, however, no objectifying diagnostic procedures are currently available. Therapeutic options for olfactory disorders are limited. Nevertheless, there are effective options consisting of olfactory training as well as various additive drug therapies. The consultation and the competent discussion with the patients are of major importance.

Indexed as

COVID-19Olfaction DisordersAnosmiaHumansQuality of LifeSARS-CoV-2

Identifiers

PMID37130532
PMCPMC10184680
OpenAlexW4367670290

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.